LearnGlossaryMarketStocksSuperinvestorsSign in

AXGN

AxoGen, Inc.

Healthcare · $2.5B market cap

Verdict

We can't put a fair value on AXGN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth3.5% a year✗
Sales growth16.0% a year✓
Free cash flow growth-38.3% a year✗
Return on invested capital-6.2%✗

Follow AXGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold AXGN. In Q1 2026, 1 trimmed. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$15.8M

341,077 shares

Mairs & Power Funds

Mairs & Power Funds · as of Q2 2026

$1.0M

22,000 shares

Moves in Q1 2026

Trimmed: First Eagle Investment Management

Insider activity

Since Sep 2, 2026: no open-market purchases and 1 sale worth $174K. Why purchases matter

Sales

TYNDALL JOSEPH A.

director · 2026-09-02

Sold

$174K

About AxoGen, Inc.

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works